Healthcare
October 1, 2018 / 7:28 AM / a year ago

BRIEF-Innate Pharma Publishes Phase 1 IPH4102 Results

1 Min Read

Oct 1(Reuters) - Innate Pharma:

* REPORTED ON SATURDAY IPH4102 PHASE 1 RESULTS IN ADVANCED CUTEANOUS T CELL LYMPHOMA

* RESULTS SHOW HIGH RESPONSE RATE AND LONG PROGRESSION-FREE SURVIVAL

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below